EASL/ILC 2019: Hot Topics bei HCC und Hepatitis
Prim. Univ.-Prof. Dr. Markus Peck-Radosavljevic, Innere Medizin und Gastroenterologie, Klinikum Klagenfurt, berichtet von den Highlights des ILC 2019. Bei Hepatitis B führt Tenofovir vs. Entecavir seltener zu Leberzellkarzinomen (HCC), neue Therapien könnten das Virus komplett eliminieren und Real-World-Daten bestätigen den moderaten Effekt der Immuntherapie bei HCC.
Abstracts, die im Video erwähnt werden:
PS-138 PD-1 targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicenter real-world cohort
Matthias Pinter, Austria
PS-137 A multicentric study on real-life impact of nivolumab in patients with hepatocellular carcinoma
Leonardo Gomes da Fonseca, Spain
PS-136 Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis
Atsushi Hiraoka, Japan
FRI-494 Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: Global OPTIMIS exploratory analysis
Markus Peck-Radosavljevic , Austria
Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers
Edward Gane, New Zealand
PS-074 A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and HBV DNA suppression in the HBV circle mouse model through elimination of cccDNA-like molecules in the mouse liver
Lu Gao , China
LB-03 Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B
Terry CF Yip, Hong Kong
International Liver Congress 2019, 10.-14.4.19, Wien